{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:02:09Z","timestamp":1787166129887,"version":"build-2736575974"},"reference-count":113,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1016\/j.ecl.2006.06.007","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T10:08:25Z","timestamp":1168423705000},"page":"469-490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Hypertension and Diabetes: Role of the Renin-Angiotensin System"],"prefix":"10.1016","volume":"35","author":[{"given":"Karin","family":"Jandeleit-Dahm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.ecl.2006.06.007_bib1","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1001\/jama.283.24.3177","article-title":"Optimizing treatment of hypertension in patients with diabetes","volume":"283","author":"Cooper","year":"2000","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ecl.2006.06.007_bib2","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1093\/ndt\/gfg339","article-title":"Aldosterone receptor blockade and the role of eplerenone: evolving perspectives","volume":"18","author":"Epstein","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.ecl.2006.06.007_bib3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study","volume":"15","author":"Pitt","year":"2001","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"10.1016\/j.ecl.2006.06.007_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3317\/jraas.2002.047","article-title":"The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design","volume":"3","author":"Chaturvedi","year":"2002","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.ecl.2006.06.007_bib5","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2337\/diab.43.10.1248","article-title":"Ambulatory blood pressure in the transition from normo- to microalbuminuria. A longitudinal study in IDDM patients","volume":"43","author":"Poulsen","year":"1994","journal-title":"Diabetes"},{"issue":"16","key":"10.1016\/j.ecl.2006.06.007_bib6","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1001\/jama.290.16.2159","article-title":"Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study","volume":"290","author":"EDIC","year":"2003","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ecl.2006.06.007_bib7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1161\/hc3001.093434","article-title":"Improvement in hypertension in patients with diabetes mellitus after kidney\/pancreas transplantation","volume":"104","author":"Elliott","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2006.06.007_bib8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(94)91904-6","article-title":"Insulin resistance: the shape of things to come","volume":"344","author":"Williams","year":"1994","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ecl.2006.06.007_bib9","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.HYP.37.4.1053","article-title":"Diabetes, hypertension, and cardiovascular disease\u2014An update","volume":"37","author":"Sowers","year":"2001","journal-title":"Hypertension"},{"issue":"9468","key":"10.1016\/j.ecl.2006.06.007_bib10","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ecl.2006.06.007_bib11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2337\/diacare.24.4.683","article-title":"Cardiovascular morbidity and mortality associated with the metabolic syndrome","volume":"24","author":"Isomaa","year":"2001","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ecl.2006.06.007_bib12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2796.2000.00724.x","article-title":"Risk factor clustering in hypertensive patients: impact of the reports of NCEP-II and second joint task force on coronary prevention on JNC-VI guidelines","volume":"248","author":"Stern","year":"2000","journal-title":"J Intern Med"},{"issue":"6","key":"10.1016\/j.ecl.2006.06.007_bib13","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1056\/NEJM198708063170605","article-title":"Insulin resistance in essential hypertension","volume":"317","author":"Ferrannini","year":"1987","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ecl.2006.06.007_bib14","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1097\/00004872-200109000-00018","article-title":"Endogenous angiotensin II suppresses insulin signaling in vascular smooth muscle cells from spontaneously hypertensive rats","volume":"19","author":"Fukuda","year":"2001","journal-title":"J Hypertens"},{"issue":"2","key":"10.1016\/j.ecl.2006.06.007_bib15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00125-003-1303-5","article-title":"Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance","volume":"47","author":"Vedovato","year":"2004","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.ecl.2006.06.007_bib16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1172\/JCI7535","article-title":"Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle","volume":"105","author":"Cusi","year":"2000","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.ecl.2006.06.007_bib17","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1161\/01.CIR.100.8.820","article-title":"Insulin stimulates both endothelin and nitric oxide activity in the human forearm","volume":"100","author":"Cardillo","year":"1999","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ecl.2006.06.007_bib18","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1172\/JCI15211","article-title":"The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance","volume":"111","author":"Vicent","year":"2003","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.ecl.2006.06.007_bib19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/qjmed\/94.6.321","article-title":"Activation of the endothelin system in insulin resistance","volume":"94","author":"Irving","year":"2001","journal-title":"QJM"},{"issue":"7","key":"10.1016\/j.ecl.2006.06.007_bib20","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2337\/diab.44.7.721","article-title":"Microvascular function in human diabetes. A physiological perspective","volume":"44","author":"Tooke","year":"1995","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2006.06.007_bib21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s003950050238","article-title":"Metabolic syndrome and hypertension: pathophysiology and molecular basis of insulin resistance","volume":"93","author":"Muller-Wieland","year":"1998","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.ecl.2006.06.007_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(98)01346-4","article-title":"Pathogenesis, prevention and treatment of diabetic nephropathy","volume":"352","author":"Cooper","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ecl.2006.06.007_bib23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1053\/ajkd.2000.16192","article-title":"Angiotensin II and its receptors in the diabetic kidney","volume":"36","author":"Burns","year":"2000","journal-title":"Am J Kidney Dis"},{"issue":"4 Pt 2","key":"10.1016\/j.ecl.2006.06.007_bib24","first-page":"F477","article-title":"Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations","volume":"265","author":"Anderson","year":"1993","journal-title":"Am J Physiol"},{"issue":"6","key":"10.1016\/j.ecl.2006.06.007_bib25","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1046\/j.1523-1755.2000.00416.x","article-title":"Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat","volume":"58","author":"Zimpelmann","year":"2000","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.ecl.2006.06.007_bib26","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1046\/j.1523-1755.2000.00038.x","article-title":"Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat","volume":"57","author":"Kelly","year":"2000","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.ecl.2006.06.007_bib27","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1046\/j.1523-1755.2000.00031.x","article-title":"Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists","volume":"57","author":"Taal","year":"2000","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.ecl.2006.06.007_bib28","doi-asserted-by":"crossref","first-page":"F343","DOI":"10.1152\/ajprenal.2001.280.2.F343","article-title":"Mechanisms underlying renoprotection during renin-angiotensin system blockade","volume":"280","author":"Taal","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ecl.2006.06.007_bib29","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s001250100546","article-title":"Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension","volume":"44","author":"Bonnet","year":"2001","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ecl.2006.06.007_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00041552-200101000-00016","article-title":"Aldosterone in renal disease","volume":"10","author":"Hostetter","year":"2001","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5","key":"10.1016\/j.ecl.2006.06.007_bib31","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/01.HYP.0000186329.92187.2e","article-title":"Renin, prorenin and the putative (pro)renin receptor","volume":"46","author":"Danser","year":"2005","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.ecl.2006.06.007_bib32","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/ki.1996.390","article-title":"Serum total renin is increased before microalbuminuria in diabetes","volume":"50","author":"Allen","year":"1996","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.ecl.2006.06.007_bib33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1523-1755.1998.00019.x","article-title":"A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR)","volume":"54","author":"Kelly","year":"1998","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.ecl.2006.06.007_bib34","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1172\/JCI21398","article-title":"Inhibition of diabetic nephropathy by a decoy peptide corresponding to the \u201chandle\u201d region for nonproteolytic activation of prorenin","volume":"114","author":"Ichihara","year":"2004","journal-title":"J\u00a0Clin Invest"},{"issue":"11","key":"10.1016\/j.ecl.2006.06.007_bib35","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI0214276","article-title":"Pivotal role of the renin\/prorenin receptor in angiotensin II production and cellular responses to renin","volume":"109","author":"Nguyen","year":"2002","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.ecl.2006.06.007_bib36","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1097\/01.ASN.0000092139.19587.51","article-title":"Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy","volume":"14","author":"Jacobsen","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ecl.2006.06.007_bib37","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.tem.2004.03.001","article-title":"ACE2, a new regulator of the renin-angiotensin system","volume":"15","author":"Burrell","year":"2004","journal-title":"Trends Endocrinol Metab"},{"issue":"6891","key":"10.1016\/j.ecl.2006.06.007_bib38","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ecl.2006.06.007_bib39","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/01.HYP.0000060689.38912.CB","article-title":"Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy","volume":"41","author":"Tikellis","year":"2003","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ecl.2006.06.007_bib40","doi-asserted-by":"crossref","first-page":"F353","DOI":"10.1152\/ajprenal.00144.2004","article-title":"The role of angiotensin converting enzyme 2 in the generation of angiotensin 1\u20137 by rat proximal tubules","volume":"288","author":"Li","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"issue":"20","key":"10.1016\/j.ecl.2006.06.007_bib41","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ecl.2006.06.007_bib42","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ecl.2006.06.007_bib43","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ecl.2006.06.007_bib44","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2006.06.007_bib45","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-134-5-200103060-00009","article-title":"Inhibitors in diabetic nephropathy trialist group: should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data","volume":"134","author":"The ACE","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ecl.2006.06.007_bib46","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.2337\/diacare.46.10.1612","article-title":"The role of angiotensin II and bradykinin in experimental diabetic nephropathy: functional and structural studies","volume":"46","author":"Allen","year":"1997","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.ecl.2006.06.007_bib47","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.1523-1755.2000.00880.x","article-title":"Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy","volume":"57","author":"Andersen","year":"2000","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2006.06.007_bib48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/080370501750066471","article-title":"The role of angiotensin II receptor antagonists in the management of diabetes","volume":"10","author":"Barnett","year":"2001","journal-title":"Blood Press"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2006.06.007_bib49","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1007\/s00592-005-0180-4","article-title":"Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study","volume":"42","author":"Barnett","year":"2005","journal-title":"Acta Diabetol"},{"issue":"1","key":"10.1016\/j.ecl.2006.06.007_bib50","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2004.03.020","volume":"148","author":"Teo","year":"2004","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.ecl.2006.06.007_bib51","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/01.hjh.0000202820.56201.e6","article-title":"Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study","volume":"24","author":"Haller","year":"2006","journal-title":"J Hypertens"},{"issue":"5","key":"10.1016\/j.ecl.2006.06.007_bib52","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/00004872-200105000-00001","article-title":"Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift","volume":"19","author":"Epstein","year":"2001","journal-title":"J Hypertens"},{"issue":"9","key":"10.1016\/j.ecl.2006.06.007_bib53","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"issue":"Suppl1","key":"10.1016\/j.ecl.2006.06.007_bib54","first-page":"A6","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"48","author":"Schjoedt","year":"2005","journal-title":"Diabetologia"},{"issue":"Suppl1","key":"10.1016\/j.ecl.2006.06.007_bib55","first-page":"A6","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy","volume":"48","author":"Jacobsen","year":"2005","journal-title":"Diabetologia"},{"issue":"Suppl1","key":"10.1016\/j.ecl.2006.06.007_bib56","first-page":"A6","article-title":"Anti-proteinuric effect of spironolactone in type 2 diabetic nephropathy: a randomized placebo-controlled study","volume":"48","author":"van den Meiracker","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.ecl.2006.06.007_bib57","doi-asserted-by":"crossref","first-page":"24A","DOI":"10.1016\/S0895-7061(02)02333-6","article-title":"Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enalapril combination therapy in diabetic hypertensives with microalbuminuria","volume":"15","author":"Epstein","year":"2002","journal-title":"Am J Hypertens"},{"issue":"1","key":"10.1016\/j.ecl.2006.06.007_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.HYP.0000110061.06674.ca","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials","volume":"43","author":"Jones","year":"2004","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.ecl.2006.06.007_bib59","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1161\/01.HYP.0000064943.51878.58","article-title":"Effect of low-dose perindopril\/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER","volume":"41","author":"Mogensen","year":"2003","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.ecl.2006.06.007_bib60","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1464-5491.2005.01596.x","article-title":"ADVANCE\u2013Action in Diabetes and Vascular Disease. Patient recruitment and characteristics of the study population at baseline","volume":"22","year":"2005","journal-title":"Diabet Med"},{"issue":"6","key":"10.1016\/j.ecl.2006.06.007_bib61","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1523-1755.2004.00620.x","article-title":"Differential effects of calcium antagonist subclasses on markers of nephropathy progression","volume":"65","author":"Bakris","year":"2004","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.ecl.2006.06.007_bib62","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/01.HYP.0000143851.23721.26","article-title":"Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study","volume":"44","author":"Bakris","year":"2004","journal-title":"Hypertension"},{"issue":"19","key":"10.1016\/j.ecl.2006.06.007_bib63","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"7274","key":"10.1016\/j.ecl.2006.06.007_bib64","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ecl.2006.06.007_bib65","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2337\/diacare.25.1.95","article-title":"Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study","volume":"25","author":"Rossing","year":"2002","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ecl.2006.06.007_bib66","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ndt\/17.6.1019","article-title":"Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy","volume":"17","author":"Jacobsen","year":"2002","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.ecl.2006.06.007_bib67","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/01.ASN.0000054495.96193.BF","article-title":"Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy","volume":"14","author":"Jacobsen","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.ecl.2006.06.007_bib68","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1046\/j.1523-1755.2003.00940.x","article-title":"Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy","volume":"63","author":"Jacobsen","year":"2003","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.ecl.2006.06.007_bib69","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.2337\/diacare.26.8.2268","article-title":"Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial","volume":"26","author":"Rossing","year":"2003","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ecl.2006.06.007_bib70","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.diabres.2005.06.010","article-title":"Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension","volume":"71","author":"Sengul","year":"2006","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.ecl.2006.06.007_bib71","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2337\/diacare.28.2.273","article-title":"Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study","volume":"28","author":"Andersen","year":"2005","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ecl.2006.06.007_bib72","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1523-1755.2005.00511.x","article-title":"Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria","volume":"68","author":"Rossing","year":"2005","journal-title":"Kidney Int"},{"issue":"9200","key":"10.1016\/j.ecl.2006.06.007_bib73","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"355","author":"Gerstein","year":"2000","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ecl.2006.06.007_bib74","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1161\/01.CIR.0000131449.94713.AD","article-title":"Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists","volume":"109","author":"Azizi","year":"2004","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.ecl.2006.06.007_bib75","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1161\/01.CIR.102.17.2087","article-title":"Independent association of high blood pressure and aortic atherosclerosis\u2014A population-based study","volume":"102","author":"Agmon","year":"2000","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ecl.2006.06.007_bib76","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/S0735-1097(01)01242-6","article-title":"The importance of age and obesity on the relation between diabetes and left ventricular mass","volume":"37","author":"Kuperstein","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"2 Part 1","key":"10.1016\/j.ecl.2006.06.007_bib77","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0002-8703(00)90239-4","article-title":"Role of hypertension, diabetes, obesity, and race in the development of symptomatic myocardial dysfunction in a predominantly minority population with normal coronary arteries","volume":"139","author":"Dwyer","year":"2000","journal-title":"Am Heart J"},{"issue":"10","key":"10.1016\/j.ecl.2006.06.007_bib78","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00125-005-1896-y","article-title":"The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus","volume":"48","author":"Dawson","year":"2005","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.ecl.2006.06.007_bib79","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0002-9149(01)01516-8","article-title":"Separate and joint effects of systemic hypertension and diabetes mellitus on left ventricular structure and function in American Indians (the strong heart study)","volume":"87","author":"Bella","year":"2001","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.ecl.2006.06.007_bib80","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1007\/s00125-005-1893-1","article-title":"Adverse effects of left ventricular hypertrophy in\u00a0the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study","volume":"48","author":"Boner","year":"2005","journal-title":"Diabetologia"},{"issue":"9489","key":"10.1016\/j.ecl.2006.06.007_bib81","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ecl.2006.06.007_bib82","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic","volume":"288","year":"2002","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ecl.2006.06.007_bib83","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archinte.165.12.1401","article-title":"Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Whelton","year":"2005","journal-title":"Arch Intern Med"},{"issue":"9489","key":"10.1016\/j.ecl.2006.06.007_bib84","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(05)67186-3","article-title":"Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)","volume":"366","author":"Poulter","year":"2005","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ecl.2006.06.007_bib85","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1161\/01.RES.87.12.1123","article-title":"Myocardial cell death in human diabetes","volume":"87","author":"Frustaci","year":"2000","journal-title":"Circ Res"},{"issue":"22","key":"10.1016\/j.ecl.2006.06.007_bib86","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1056\/NEJMra032865","article-title":"Hypertensive retinopathy","volume":"351","author":"Wong","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ecl.2006.06.007_bib87","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1167\/iovs.04-0069","article-title":"Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk In Communities study","volume":"45","author":"Wong","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.ecl.2006.06.007_bib88","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s001250051594","article-title":"UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis","volume":"44","author":"Stratton","year":"2001","journal-title":"Diabetologia"},{"issue":"7160","key":"10.1016\/j.ecl.2006.06.007_bib89","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ecl.2006.06.007_bib90","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/bjo.80.2.159","article-title":"Demonstration of renin mrna, angiotensinogen mrna, and angiotensin converting enzyme mrna expression in the human eye\u2014evidence for an intraocular renin-angiotensin system","volume":"80","author":"Wagner","year":"1996","journal-title":"Br J Ophthalmol"},{"issue":"22","key":"10.1016\/j.ecl.2006.06.007_bib91","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ecl.2006.06.007_bib92","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1210\/en.2003-0967","article-title":"Connective tissue growth factor is up-regulated in the diabetic retina: amelioration by angiotensin-converting enzyme inhibition","volume":"145","author":"Tikellis","year":"2004","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.ecl.2006.06.007_bib93","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3317\/jraas.2005.003","article-title":"The DIabetic REtinopathy Candesartan Trial (DIRECT) Programme","volume":"6","author":"Sj\u00f8lie","year":"2005","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"7","key":"10.1016\/j.ecl.2006.06.007_bib94","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s001250100556","article-title":"The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats","volume":"44","author":"Nagisa","year":"2001","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.ecl.2006.06.007_bib95","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s001250051539","article-title":"Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes","volume":"43","author":"Gilbert","year":"2000","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.ecl.2006.06.007_bib96","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1161\/01.HYP.36.6.1099","article-title":"Retinal neovascularization is prevented by blockade of the renin-angiotensin system","volume":"36","author":"Moravski","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2006.06.007_bib97","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0140-6736(97)06209-0","article-title":"Effect of lisinopril on progression of retinopathy in people with type 1 diabetes","volume":"351","author":"Chaturvedi","year":"1998","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.ecl.2006.06.007_bib98","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","article-title":"Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus","volume":"342","author":"Gress","year":"2000","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ecl.2006.06.007_bib99","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00002018-199818060-00005","article-title":"Drug administration in patients with diabetes mellitus. Safety considerations","volume":"18","author":"Gilbert","year":"1998","journal-title":"Drug Saf"},{"issue":"15","key":"10.1016\/j.ecl.2006.06.007_bib100","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.286.15.1882","article-title":"Ramipril and the development of diabetes","volume":"286","author":"Yusuf","year":"2001","journal-title":"JAMA"},{"issue":"9153","key":"10.1016\/j.ecl.2006.06.007_bib101","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ecl.2006.06.007_bib102","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/00004872-200403000-00029","article-title":"Development of diabetes is retarded by ACE inhibition in hypertensive patients\u2013a subanalysis of the Captopril Prevention Project (CAPPP)","volume":"22","author":"Niklason","year":"2004","journal-title":"J Hypertens"},{"issue":"7","key":"10.1016\/j.ecl.2006.06.007_bib103","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","article-title":"A comparison of outcomes with angiotensin-converting\u2013enzyme inhibitors and diuretics for hypertension in the elderly","volume":"348","author":"Wing","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ecl.2006.06.007_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/S0895-7061(03)00110-9","article-title":"Diabetes and cardiovascular outcomes in elderly subjects treated with ACE-inhibitors or diuretics: findings from the 2nd Australian National Blood Pressure Study","volume":"16","author":"Reid","year":"2003","journal-title":"Am J Hypertens"},{"issue":"9","key":"10.1016\/j.ecl.2006.06.007_bib105","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/01.CIR.0000054611.89228.92","article-title":"Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD)","volume":"107","author":"Vermes","year":"2003","journal-title":"Circulation"},{"issue":"9426","key":"10.1016\/j.ecl.2006.06.007_bib106","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ecl.2006.06.007_bib107","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.hjh.0000160198.05416.72","article-title":"Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes","volume":"23","author":"Jandeleit-Dahm","year":"2005","journal-title":"J Hypertens"},{"issue":"4","key":"10.1016\/j.ecl.2006.06.007_bib108","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11906-005-0021-4","article-title":"Differential effects of antihypertensive drugs on new-onset diabetes?","volume":"7","author":"Elliott","year":"2005","journal-title":"Curr Hypertens Rep"},{"issue":"3","key":"10.1016\/j.ecl.2006.06.007_bib109","first-page":"179","article-title":"The prevention of type 2 diabetes: what is the evidence?","volume":"30","author":"Chiasson","year":"2005","journal-title":"Minerva Endocrinol"},{"issue":"9","key":"10.1016\/j.ecl.2006.06.007_bib110","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00125-004-1485-5","article-title":"Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial","volume":"47","author":"Gerstein","year":"2004","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ecl.2006.06.007_bib111","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bbrc.2004.02.023","article-title":"Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats","volume":"316","author":"Ko","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ecl.2006.06.007_bib112","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.biocel.2005.08.007","article-title":"Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes","volume":"38","author":"Tikellis","year":"2006","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"10.1016\/j.ecl.2006.06.007_bib113","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2337\/diabetes.53.4.989","article-title":"Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat","volume":"53","author":"Tikellis","year":"2004","journal-title":"Diabetes"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852906000478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852906000478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:29:14Z","timestamp":1760174954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852906000478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":113,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S0889852906000478"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2006.06.007","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypertension and Diabetes: Role of the Renin-Angiotensin System","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2006.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}